Common mutually exclusive driver mutations within Janus Kinase 2 (JAK2), Calreticulin (CALR) and myeloproliferative leukaemia virus oncogene (MPL) are often identified in MPN patients. This evidence concerns the gene JAK2 and myeloproliferative disorder.